Trump administration's final Medicare pricing rule limits savings, covering only four firms

The Trump administration released a final rule intended to lower Medicare prices for drugs administered in physician offices. The rule is part of the Global Benchmark for Efficient Drug Pricing (GLOBE) pilot, one of two mandatory programs aimed at aligning U.S. drug prices with those in other wealthy nations.

The rule applies to just four pharmaceutical companies and excludes firms that have already entered voluntary most‑favored‑nation pricing deals for Medicaid. By limiting participation, the potential reach of the price‑cutting mechanism is sharply reduced.

Analysts note that the final rule delivers roughly 96% less savings than the original proposal, casting doubt on its ability to meaningfully curb Medicare drug costs. Critics argue the watered‑down approach undermines the administration’s broader pricing agenda.

The companion GUARD pilot remains in the proposal stage, leaving the overall impact of the administration’s pricing strategy uncertain.